The FDA approved Foundayo (orforglipron) on April 1, 2026, for adults with obesity or overweight with at least one weight-related comorbid condition.312 Foundayo is an oral GLP-1 receptor agonist that can be taken any time of day without the food, beverage, and oral-medication timing requirements in the Rybelsus label.3411 The distinction matters for anyone who has tried to plan a training morning around Rybelsus's 30-minute empty-stomach rule.
01Orforglipron activates the GLP-1 receptor as a small molecule
Rybelsus contains semaglutide, a peptide GLP-1 receptor agonist. It is co-formulated with salcaprozate sodium (SNAC), which facilitates semaglutide absorption. The label requires an empty-stomach morning dose with up to 4 ounces of water, no other liquids, and a wait of at least 30 minutes before food, beverages, or other oral medications.4
Orforglipron is a nonpeptide small molecule that binds to and activates the human GLP-1 receptor.6 Foundayo's label allows once-daily administration with or without food and requires the tablet to be swallowed whole. The manufacturer describes administration at any time of day without food or water restrictions.311
02Foundayo removes the Rybelsus fasting restriction
| Factor | Rybelsus (oral semaglutide) | Foundayo (orforglipron) |
|---|---|---|
| Drug class | Peptide semaglutide with SNAC4 | Nonpeptide small molecule6 |
| Food and water rule | Empty stomach in the morning, up to 4 oz of water, no other liquids, then wait at least 30 minutes before food, beverages, or oral medications4 | No food or water restriction, take once daily with or without food311 |
| Timing | Morning | Any time of day11 |
| Administration | Swallow whole | Swallow whole, do not break, crush, or chew3 |
For someone training early, Rybelsus requires a wait of at least 30 minutes after the tablet before food, beverages, or other oral medications.4 Foundayo can be taken once daily with or without food, at any time of day.311
03ATTAIN-1 measured 72-week weight loss at three doses
ATTAIN-1 randomized 3,127 adults with obesity or overweight, without diabetes, across nine countries to orforglipron 6 mg, 12 mg, or 36 mg, or placebo, for 72 weeks.1 All active-arm participants started at 1 mg and stepped up every four weeks to their assigned dose. The trial used capsules at these strengths, not the tablets Foundayo ships in.1
The trial reported two ways of measuring weight change at week 72, called estimands. The treatment-regimen estimand counts everyone randomized, including people who stopped the drug or started a different weight-management treatment. The efficacy estimand models what weight loss would have looked like if every participant stayed on the assigned drug without those events.12
| Dose | Weight change at 72 weeks (treatment-regimen estimand) | Weight change at 72 weeks (efficacy estimand) |
|---|---|---|
| Placebo | −2.1% | −0.9% (2.2 lb average) |
| 6 mg | −7.5% | −7.8% |
| 12 mg | −8.4% | −9.3% |
| 36 mg | −11.2% | −12.4% (27.3 lb average) |
The two columns are estimand-based analyses, not observed completer and non-completer groups. The 12.4 percent and 27.3-pound figures should therefore not be described as outcomes among people who stayed on treatment.12
04GI side effects vary by Foundayo dose
All four listed GI events were more common than placebo, but their dose patterns were not uniform.2
| Side effect | 6 mg | 12 mg | 36 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.9% | 35.9% | 33.7% | 10.4% |
| Constipation | 21.7% | 29.8% | 25.4% | 9.3% |
| Diarrhea | 21.0% | 22.8% | 23.1% | 9.6% |
| Vomiting | 13.0% | 21.4% | 24.0% | 3.5% |
Discontinuation due to adverse events was 5.3 percent at 6 mg, 7.9 percent at 12 mg, and 10.3 percent at 36 mg, versus 2.7 percent on placebo.2 The trial authors described the adverse-event profile as consistent with other GLP-1 receptor agonists. FDA labeling states that adverse-reaction rates from separate drug trials cannot be directly compared.13 Foundayo delays gastric emptying and its label warns of gastrointestinal adverse reactions.3 The day-to-day management of these symptoms, timing meals around nausea windows, and rebuilding appetite after a rough week, is covered in Eating Through GLP-1 Side Effects.
05Foundayo tablet doses differ from ATTAIN-1 capsule doses
Foundayo's FDA label starts patients at 0.8 mg once daily, then increases after at least 30 days at each dose level to 2.5 mg, then 5.5 mg, with optional further increases to 9 mg, 14.5 mg, or a maximum of 17.2 mg based on treatment response and tolerability.3 Those numbers look nothing like the 6, 12, and 36 mg doses tested in ATTAIN-1, because the commercial product ships as a tablet while the trial used capsules. A bioequivalence study links the two formulations, with the 17.2 mg tablet producing the same bloodstream drug levels as the 36 mg trial capsule.35 If you are reading trial results and a prescription bottle side by side, the mg numbers will not line up.
06Use protein and resistance training guardrails on Foundayo
ATTAIN-1 included a reduced-calorie diet and increased physical activity, but it did not test a specific protein target, fiber target, hydration target, or resistance-training protocol.13 A 2025 joint advisory recommends prioritizing adequate protein and structured strength training during GLP-1 therapy. It discusses 1.2 to 1.6 g/kg/day as a proposed higher protein target during active weight reduction, with the basis for calculation requiring individualization.9 The full framework, including how to structure meals when appetite suppression makes eating enough protein feel like a chore, is in How to Preserve Muscle on GLP-1 Medications.
ATTAIN-1 included a voluntary DXA subgroup of 171 participants. In the pooled orforglipron groups, total fat mass fell 13.8 percent and total lean mass fell 4.5 percent at week 72. The analysis estimated that 73.1 percent of weight reduction came from fat mass and 26.9 percent from lean mass. The subgroup was small, voluntary, and not adjusted for type 1 error.1 These results provide body-composition data for a subgroup, not a head-to-head comparison with injectable GLP-1 drugs. Direct oral-versus-injectable lean-mass comparisons are unavailable.1
ClinicalTrials.gov lists ATTAIN-Outcomes (NCT07241390) as a recruiting event-driven cardiovascular-outcomes trial in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease. No results are posted in the registry.8
07Foundayo versus other GLP-1 medications
The rows below summarize results from separate trials. Population, dose, duration, background treatment, and estimand differ across the studies, so the figures are not a head-to-head efficacy ranking.134710
| Drug | Form and administration | Weight result cited |
|---|---|---|
| Rybelsus (oral semaglutide) | Daily tablet, empty stomach in the morning with up to 4 oz of water, no other liquids, then a 30-minute wait before food, beverages, or oral medications4 | −3.8 kg at week 26 (14 mg, type 2 diabetes trial)4 |
| Foundayo (orforglipron) | Daily tablet, no food or water restriction311 | −11.2% at week 72 (36 mg trial capsule, treatment-regimen estimand, obesity or overweight without diabetes)1 |
| Wegovy oral semaglutide | Daily tablet, empty stomach in the morning with up to 4 oz of water, no other liquids, then wait at least 30 minutes before food, beverages, or oral medications7 | −13.6% at week 64 (25 mg, obesity or overweight with comorbidity, ITT LSMean)7 |
| Wegovy HD (injectable semaglutide) | Weekly injection, any time of day, with or without meals7 | −18.8% at week 72 (7.2 mg, obesity trial, ITT LSMean)7 |
| Zepbound (injectable tirzepatide) | Weekly injection, any time of day, with or without meals10 | −20.9% at week 72 (15 mg, obesity or overweight trial, ITT LSMean)10 |
Foundayo's distinguishing administration feature is the absence of the fasting and beverage restrictions in the Rybelsus and oral Wegovy labels.34711 The weight results above come from separate trials and should not be interpreted as direct treatment comparisons.14710 The same dose titration questions that come up with semaglutide and tirzepatide, including what nutrition data is worth tracking before a scheduled increase, are covered in GLP-1 dose titration and the nutrition data worth checking before each increase.
Footnotes
Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. Published September 16, 2025, 393(18), 1796-1806. NEJM article PDF. DOI: 10.1056/NEJMoa2511774
Back to textBack to text 2Back to text 3Back to text 4Back to text 5Back to text 6Back to text 7Back to text 8Back to text 9Back to text 10Back to text 11Back to text 12Back to text 13Back to text 14Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine [press release]. September 16, 2025. Lilly Investor Relations
Back to textBack to text 2Back to text 3Back to text 4Back to text 5Back to text 6Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, prescribing information. U.S. Food and Drug Administration, initial U.S. approval 2026, revised April 2026. FDA label. DailyMed
Back to textBack to text 2Back to text 3Back to text 4Back to text 5Back to text 6Back to text 7Back to text 8Back to text 9Back to text 10Back to text 11Back to text 12Back to text 13Back to text 14Back to text 15Novo Nordisk. RYBELSUS (semaglutide) tablets, prescribing information. U.S. Food and Drug Administration, revised December 2024. FDA label
Back to textBack to text 2Back to text 3Back to text 4Back to text 5Back to text 6Back to text 7Back to text 8Back to text 9Back to text 10Back to text 11Ma X, Li YG, Raha S, Sperry DC, Coutant DE, Bhattachar S. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. Diabetes Obes Metab. First published April 17, 2026, 28(7), 5803-5809. PubMed. DOI: 10.1111/dom.70783
Back to textBack to text 2Kawai T, Sun B, Yoshino H, et al. Structural Basis for GLP-1 Receptor Activation by LY3502970, an Orally Active Nonpeptide Agonist. Proc Natl Acad Sci U S A. 2020, 117(47), 29959-29967. PubMed. DOI: 10.1073/pnas.2014879117
Back to textBack to text 2Back to text 3Novo Nordisk. WEGOVY (semaglutide) tablets and injection, prescribing information. U.S. Food and Drug Administration, revised June 2026. FDA label
Back to textBack to text 2Back to text 3Back to text 4Back to text 5Back to text 6Back to text 7ClinicalTrials.gov. ATTAIN-Outcomes, NCT07241390. Registry record
Back to textMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obes Pillars. 2025, 15, 100181. PubMed. doi:10.1016/j.obpill.2025.100181
Back to textBack to text 2Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. U.S. Food and Drug Administration, revised January 2026. FDA label
Back to textBack to text 2Back to text 3Back to text 4Eli Lilly and Company. Foundayo (orforglipron) HCP overview. 2026. Foundayo HCP
Back to textBack to text 2Back to text 3Back to text 4Back to text 5Back to text 6Back to text 7U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program [FDA news release]. April 1, 2026. FDA
Back to text
